Note: On January 30, 2025 the FDA approved the first-in-class non-opioid analgesic Journavx (suzetrigine) for the treatment of moderate to severe acute pain in adults. The novel drug reduces pain by ...
A new study adds to evidence which suggests treating breast cancer patients with sodium channel blockers could be a promising future treatment to prevent the spread of cancer during the gap between ...
A new study on live tissue cells is the first to reveal how channels that allow sodium to enter into breast cancer cells enable tumours to grow and spread. The discovery adds to evidence which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results